AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12801569 — intervention group
Group type: EXPERIMENTAL
Intervention: Density Gradient Centrifugation (DGC)
Number of subjects: 311
Study 12801569 — intervention group
Group type: COMPARATOR
Intervention: Wash only
Number of subjects: 311
Study 12801569 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 311
Study 10047935 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/d of deprenyl
Number of subjects: 14
Study 10047935 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d of deprenyl
Number of subjects: 14
Study 10047935 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 healthy volunteers, mean age 63.1 +/- 1.2 years)
Number of subjects: 14
Study 7571176 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWL in situ
Number of subjects: 180
Study 7571176 — intervention group
Group type: COMPARATOR
Intervention: Retrograde manipulation before ESWL
Number of subjects: 180
Study 7571176 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde manipulation for stones < 8 mm
Number of subjects: 180
Study 7571176 — intervention group
Group type: EXPERIMENTAL
Intervention: Auxiliary procedures (DJ catheter placement)
Number of subjects: 180
Study 2076733 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 128
Study 2076733 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 128
Study 7267221 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Blood phenylalanine target 1.0 to 5.4 mg/100 ml
Number of subjects: 132
Study 7267221 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Blood phenylalanine target 5.5 to 9.9 mg/100 ml
Number of subjects: 132
Study 7267221 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment groups
Number of subjects: 132
Study 7267221 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment factors
Number of subjects: 132
Study 31217380 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity ergometer exercise at 80% VO2peak for 60 min
Number of subjects: 9
Study 31217380 — intervention group
Group type: COMPARATOR
Intervention: Control (rest for 60 min)
Number of subjects: 9
Study 30955702 — intervention group
Group type: EXPERIMENTAL
Intervention: real-tDCS
Number of subjects: 56
Study 30955702 — intervention group
Group type: COMPARATOR
Intervention: sham-tDCS
Number of subjects: 56
Study 26907843 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning Training Group (MTG, 07:00-08:00 hours)
Number of subjects: 20
Study 26907843 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening Training Group (ETG, 17:00-18:00 hours)
Number of subjects: 20
Study 26907843 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not explicitly mentioned)
Number of subjects: 20
Study 24170180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg/day
Number of subjects: 505
Study 24170180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 80-120 mg/day
Number of subjects: 505
Study 24170180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study 24170180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg/day and 80-120 mg/day
Number of subjects: 505
Study 24170180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 505
Study 22424912 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release hydromorphone (IR) 5 times/day
Number of subjects: 148
Study 22424912 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily hydromorphone extended-release (ER) at full dose
Number of subjects: 148
Study 22424912 — intervention group
Group type: COMPARATOR
Intervention: Once-daily hydromorphone extended-release (ER) at half dose
Number of subjects: 148
Study 19022580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 50
Study 19022580 — intervention group
Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SPT)
Number of subjects: 50
Study 17226906 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (400 mg bid for 7 d every month) plus dietary fiber supplementation (at least 20 gr/d)
Number of subjects: 307
Study 17226906 — intervention group
Group type: COMPARATOR
Intervention: Dietary fiber supplementation alone
Number of subjects: 307
Study 15128011 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (estrogen-progestin combination)
Number of subjects: 20000
Study 12373029 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intracranial pressure
Number of subjects: 3866
Study 12373029 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent cerebral ischemia
Number of subjects: 3866
Study 12373029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever >38 degrees C
Number of subjects: 3866
Study 12373029 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe arterial hypertension
Number of subjects: 3866
Study 12373029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia
Number of subjects: 3866
Study 12373029 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain stem infarction and large-artery atherosclerosis
Number of subjects: 3866
Study 9638982 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy for gastrointestinal bleeding
Number of subjects: 36
Study 9638982 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for gastrointestinal bleeding
Number of subjects: 36
Study 9638982 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization for gastrointestinal bleeding
Number of subjects: 36
Study 9638982 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for peritonitis
Number of subjects: 36
Study 9638982 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality in patients with gastrointestinal emergencies
Number of subjects: 36
Study 9638982 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic factors
Number of subjects: 36
Study 8046277 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐force, high‐velocity, low‐amplitude manipulation procedure
Number of subjects: 201
Study 8046277 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐force, high‐velocity, low‐amplitude procedure
Number of subjects: 201
Study 8046277 — intervention group
Group type: COMPARATOR
Intervention: Educational lectures on lower back pain
Number of subjects: 201
Study 8046277 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 201
Study 2648190 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE)
Number of subjects: 64
Study 2648190 — intervention group
Group type: COMPARATOR
Intervention: Butorphanol
Number of subjects: 64
Study 2648190 — intervention group
Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 64
Study 29553002 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype threat condition
Number of subjects: 50
Study 29553002 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 50
Study 26508098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dual-task (CDT) training
Number of subjects: 30
Study 26508098 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function (EF) training
Number of subjects: 30
Study 26508098 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 24590644 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg intravenously every 4 weeks)
Number of subjects: 645
Study 24590644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 645
Study 24590644 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 645
Study 22749044 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 μg once daily) + Salmeterol (50 μg twice daily) (T + S)
Number of subjects: 309
Study 22749044 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol + Fluticasone (50/500 μg twice daily) (S + F)
Number of subjects: 309
Study 20053144 — intervention group
Group type: COMPARATOR
Intervention: Fosinopril alone (F group)
Number of subjects: 124
Study 20053144 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril+indapamide (F/I group)
Number of subjects: 124
Study 20053144 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril alone after conversion from Fosinopril+indapamide (F/I group)
Number of subjects: 124
Study 18514974 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-9
Number of subjects: 212
Study 18514974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 16319156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular sodium hyaluronate (SH) 10 mg
Number of subjects: 60
Study 16319156 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular glucocorticoids (triamcinolone acetonide; TA) 10 mg
Number of subjects: 60
Study 12873934 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil 0.2 micro g. kg(‐1). min(‐1) (20 mL/h) for 60 min
Number of subjects: 32
Study 12873934 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 20 mL/h for 60 min (Control)
Number of subjects: 32
Study 10526249 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5mg once daily for 12 months
Number of subjects: 110
Study 10526249 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 250mg twice daily for 12 months
Number of subjects: 110
Study 8879439 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (two 600-mg tablets once per day for 8 weeks)
Number of subjects: 10
Study 8503391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (15 mg/day for 14 days)
Number of subjects: 14
Study 8503391 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 6)
Number of subjects: 14
Study 3689013 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg intrarectally every 6-8 hours until postoperative day 3)
Number of subjects: 14
Study 3689013 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 14
Study 3689013 — intervention group
Group type: COMPARATOR
Intervention: Control (16 patients who did not receive indomethacin)
Number of subjects: 14
Study 31920015 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia patients
Number of subjects: 14736
Study 31920015 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia patients aged < 70 years
Number of subjects: 14736
Study 31920015 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia patients aged 70-79 years
Number of subjects: 14736
Study 31920015 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia patients aged 80-89 years
Number of subjects: 14736
Study 31920015 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia patients aged ≥ 90 years
Number of subjects: 14736
Study 31920015 — intervention group
Group type: EXPERIMENTAL
Intervention: Men pneumonia patients
Number of subjects: 14736
Study 31920015 — intervention group
Group type: EXPERIMENTAL
Intervention: Women pneumonia patients
Number of subjects: 14736
Study 31920015 — intervention group
Group type: COMPARATOR
Intervention: Non-pneumonia patients
Number of subjects: 14736
Study 30026562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI) group (n=15) performed one immersion at 10°C for 20 min post-exercise and every 24 h for 72 h
Number of subjects: 30
Study 30026562 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=15) remained seated during corresponding periods
Number of subjects: 30
Study 28775197 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% kanuka honey
Number of subjects: 950
Study 28775197 — intervention group
Group type: COMPARATOR
Intervention: 5% aciclovir cream
Number of subjects: 950
Study 25541248 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step self-etch adhesive (Futurabond M, 1-SE)
Number of subjects: 40
Study 25541248 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step etch-and-rinse adhesive (Solobond M, 2-ER)
Number of subjects: 40
Study 25541248 — intervention group
Group type: COMPARATOR
Intervention: Four-step etch-and-rinse adhesive (Syntac classic, 4-ER)
Number of subjects: 40
Study 23953929 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg hydrocortisone
Number of subjects: 64
Study 23953929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 21788129 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening with a cut-off of 3.0-4.0 ng/ml at a 2-7 year interval
Number of subjects: 61604
Study 19114384 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based alcohol education program
Number of subjects: 3216
Study 19114384 — intervention group
Group type: COMPARATOR
Intervention: Control group (completed a survey and knowledge test)
Number of subjects: 3216
Study 16960268 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 5 mg iv with epidural injection of 0.25% bupivacaine 8 mL and normal saline 2 mL (Control)
Number of subjects: 94
Study 16960268 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline 2 mL iv with epidural injection of 0.25% bupivacaine 8 mL and dexamethasone 5 mg in normal saline 2 mL (D1)
Number of subjects: 94
Study 16960268 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline 2 mL iv with epidural injection of dexamethasone 5 mg in normal saline 10 mL (D2)
Number of subjects: 94
Study 16960268 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone groups (D1, D2)
Number of subjects: 94
Study 15485402 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg
Number of subjects: 830
Study 15485402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 830
Study 15485402 — intervention group
Group type: COMPARATOR
Intervention: Control (matching placebo for fosinopril)
Number of subjects: 830
Study 15485402 — intervention group
Group type: COMPARATOR
Intervention: Control (matching placebo for pravastatin)
Number of subjects: 830
Study 15485402 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham risk score <20%
Number of subjects: 830
Study 15485402 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuminuria
Number of subjects: 830
Study 15485402 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham risk score
Number of subjects: 830
Study 15485402 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Framingham score and urinary albumin excretion
Number of subjects: 830
Study 11011783 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.5 g of supplemental arginine
Number of subjects: 32
Study 11011783 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 g of supplemental arginine
Number of subjects: 32
Study 11011783 — intervention group
Group type: COMPARATOR
Intervention: 0 g of supplemental arginine (Control)
Number of subjects: 32
Study 11011783 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.5 g and 17 g of supplemental arginine
Number of subjects: 32
Study 11011783 — intervention group
Group type: EXPERIMENTAL
Intervention: All arginine supplementation groups
Number of subjects: 32
Study 8707022 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (mean daily dose of 13 ± 1.5 mg/Kg; Group A: 102 patients)
Number of subjects: 300
Study 8707022 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (mean daily dose of 3 ± 0.4 mg/Kg; Group B: 106 patients)
Number of subjects: 300
Study 8707022 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C: 92 patients)
Number of subjects: 300
Study 8707022 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol compared to Propafenone
Number of subjects: 300
Study 8707022 — intervention group
Group type: COMPARATOR
Intervention: Propafenone and Sotalol compared to Placebo
Number of subjects: 300
Study 8707022 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Placebo)
Number of subjects: 300
Study 1901437 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 44
Study 1901437 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty
Number of subjects: 44
Study 1901437 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with inferior wall AMI)
Number of subjects: 44
Study 6626636 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulus A (counted stimulus)
Number of subjects: 0
Study 6626636 — intervention group
Group type: COMPARATOR
Intervention: Auditory stimulus B (not-to-be-counted stimulus)
Number of subjects: 0
Study 31086250 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release (MFR)
Number of subjects: 30
Study 31086250 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 30
Study 28918362 — intervention group
Group type: EXPERIMENTAL
Intervention: High Volume (HV) Resistance Training
Number of subjects: 376
Study 28918362 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Volume (LV) Resistance Training
Number of subjects: 376
Study 28918362 — intervention group
Group type: COMPARATOR
Intervention: Both groups (HV and LV)
Number of subjects: 376
Study 25856221 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (Scarborough Fair Diet)
Number of subjects: 50
Study 25856221 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (generic range of vegetables/herbs/fruit)
Number of subjects: 50
Study 25856221 — intervention group
Group type: COMPARATOR
Intervention: Group C (usual diet)
Number of subjects: 50
Study 25856221 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 50
Study 22817664 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity, pulsed, electromagnetic fields (PEF) treatment for 10 minutes (mean intensity 1.5 mW)
Number of subjects: 42
Study 22817664 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 10 minutes
Number of subjects: 42
Study 21059637 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HD-CT) with one cycle of standard dose cisplatin, etoposide, and ifosfamide (VIP) plus three cycles of high-dose VIP followed by stem-cell infusion
Number of subjects: 131
Study 21059637 — intervention group
Group type: COMPARATOR
Intervention: Standard dose BEP (cisplatin, etoposide, and bleomycin)
Number of subjects: 131
Study 21059637 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HD-CT)
Number of subjects: 131
Study 21059637 — intervention group
Group type: COMPARATOR
Intervention: Standard dose BEP
Number of subjects: 131
Study 19717851 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker continuation
Number of subjects: 169
Study 19717851 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker discontinuation
Number of subjects: 169
Study 17438089 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat
Number of subjects: 74
Study 14766592 — intervention group
Group type: EXPERIMENTAL
Intervention: Sourdough bread made from a mixture of wheat (30%) and nontoxic oat, millet, and buckwheat flours started with selected lactobacilli after 24 hours of fermentation.
Number of subjects: 17
Study 14766592 — intervention group
Group type: COMPARATOR
Intervention: Baker's yeast bread containing ca. 2 g of gluten.
Number of subjects: 17
Study 11701466 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin-ER (1 g)
Number of subjects: 139
Study 11701466 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin-ER (2 g)
Number of subjects: 139
Study 11701466 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil (1.2 g)
Number of subjects: 139
Study 11701466 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin-ER and Gemfibrozil
Number of subjects: 139
Study 9399024 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma total antioxidant capacity (TAOC)
Number of subjects: 728
Study 9399024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of water spinach
Number of subjects: 728
Study 9399024 — intervention group
Group type: COMPARATOR
Intervention: Presence of hypertension or cardiovascular disease
Number of subjects: 728
Study 7983641 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose prednisone (5 to 10 mg/day)
Number of subjects: 36
Study 7983641 — intervention group
Group type: COMPARATOR
Intervention: No prednisone
Number of subjects: 36
Study 7983641 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose prednisone
Number of subjects: 36
Study 7983641 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly male controls
Number of subjects: 36
Study 3185283 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure porcine insulin
Number of subjects: 105
Study 3185283 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed bovine/porcine insulin
Number of subjects: 105
Study 31898296 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized-marker method
Number of subjects: 0
Study 31898296 — intervention group
Group type: COMPARATOR
Intervention: Single imputation using state space representation
Number of subjects: 0
Study 31898296 — intervention group
Group type: COMPARATOR
Intervention: Multiple imputation based on regression
Number of subjects: 0
Study 31548792 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 6 weeks
Number of subjects: 7
Study 31548792 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Training (MIT) for 6 weeks
Number of subjects: 7
Study 29390529 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment
Number of subjects: 27
Study 29390529 — intervention group
Group type: COMPARATOR
Intervention: SRP (scaling and root planing)
Number of subjects: 27
Study 29390529 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Er:YAG laser and SRP)
Number of subjects: 27
Study 24595735 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentoring to promote exercise
Number of subjects: 10
Study 22893351 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental amalgam exposure
Number of subjects: 0
Study 22893351 — intervention group
Group type: COMPARATOR
Intervention: No dental amalgam exposure
Number of subjects: 0
Study 21193190 — intervention group
Group type: EXPERIMENTAL
Intervention: LT4 treatment (50 μg administered from the first day of controlled ovarian stimulation for IVF/ICSI)
Number of subjects: 64
Study 21193190 — intervention group
Group type: EXPERIMENTAL
Intervention: LT4 treatment
Number of subjects: 64
Study 21193190 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 18589404 — intervention group
Group type: COMPARATOR
Intervention: THC
Number of subjects: 15
Study 18589404 — intervention group
Group type: COMPARATOR
Intervention: CBD
Number of subjects: 15
Study 18589404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15